When it comes to the future of living healthier for longer, the investment world is paying close attention.
Longevity.Technology, a UK-based research and media group specializing in this space, recently released their 2024 Annual Longevity Investment Report — a detailed snapshot of how funding is flowing into technologies aimed at extending our healthy years.
Diving Deep Into the Longevity Sector
This report isn’t just about numbers; it breaks down the longevity industry into 25 distinct areas.
These range from cutting-edge fields like senotherapeutics (which target aging cells) to reproductive longevity, immunity, and even partial cellular reprogramming.
By looking at both private and public investments over the past decade, the report gives us a clear view of where money is going, who’s investing, and what trends are shaping the sector.
Investment Rebounds After a Slow 2023
After a slowdown in 2023, 2024 has seen a strong rebound.
Total funding in the longevity field hit $8.49 billion, spread across 331 deals.
The year started off with a bang—Q1 alone raised $3.74 billion, setting the tone for steady growth throughout the rest of the year.
Later-stage venture capital deals led the way, making up about a third of all the money invested.
The United States Remains the Longevity Hotspot
No surprise here — the U.S. continues to dominate the longevity scene.
It’s home to 57% of longevity-focused companies and accounted for a whopping 84% of all deal volume in 2024.
Investors showed strong interest in platform technologies, which support drug discovery and development pipelines.
Longevity discovery platforms alone raised more than $2 billion, highlighting a shift towards foundational tools that can accelerate innovation across the sector.
Big Moves in Longevity Biotech and Consumer Tech
2024 wasn’t short on exciting milestones. BioAge Labs and Jupiter Neurosciences went public with successful IPOs, while startups like Rubedo Life Sciences, specializing in senotherapeutics, and Loyal, focused on dog longevity biotech, raised impressive funding rounds.
Consumer-focused companies also grabbed attention: ŌURA, known for its smart rings, closed a $200 million Series D, and Function Health, a personalized prevention platform, raised $53 million in a star-studded Series A round.
Key Takeaways from the 2024 Report
-
Total funding hit $8.49 billion, more than doubling the $3.82 billion from 2023
-
The number of deals was slightly down to 325 from 331 in the previous year
-
Q1 2024 was the standout quarter with $3.74 billion raised
-
Later-stage venture capital made up 31% of all financing
-
The U.S. dominated with 57% of longevity companies and 84% of deal volume
-
Longevity discovery platforms topped the charts with $2.65 billion in funding
What’s Next for Longevity Investment?
This report paints a promising picture of a sector bouncing back with momentum and maturity.
As the science behind longevity advances, so too does investor confidence in technologies that might one day help us all live longer, healthier lives.
It’ll be fascinating to watch where this space heads next — both in terms of breakthrough science and the money powering it.